Key Facts Surrounding This News Item
- EOLS had returned 0.00% year-to-date leading up to today’s news, versus a +2.00% return from the benchmark S&P 500 during the same period.
More Info About Evolus, Inc. (EOLS)
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California. View our full EOLS ticker page with ratings, news, and more.